Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Eli Lilly & Co. : Lilly quarterly sales, profit beats forecasts

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2012 | 02:01pm CEST

Eli Lilly & Co's quarterly profit fell on plunging sales of its Zyprexa schizophrenia drug, but results handily topped Wall Street forecasts, helped by strong sales of anti-depressant Cymbalta and demand for the company's animal health products.

The earnings beat, relative to investor expectations, was also due to cost controls, surging demand in China for its products and because Zyprexa's decline was not as steep as had been feared, said company spokesman Mark Taylor.

The Indianapolis drugmaker said on Wednesday it earned $1.01 billion, or 91 cents per share in the first quarter. That compared with $1.06 billion, or 95 cents per share, in the year-earlier period, when the company took a number of restructuring and research-related charges.

Excluding special items, Lilly earned 92 cents per share. Analysts, on average, had expected 78 cents per share, according to Thomson Reuters I/B/E/S.

The company's shares rose 2.2 percent in premarket trading.

"Lilly just reported what looks like a solid first quarter," ISI Group analyst Mark Schoenebaum said in a research note.

But Schoenebaum predicted its shares would not react in a major way since investors are more focused on the company's progress in developing solanezumab, its experimental Alzheimer's disease treatment, than on quarterly earnings.

Data from the drug's late-stage trial is expected later this year. Although the drug is considered to be a long shot, investors say it would have huge sales potential if shown to slow progress of the memory-robbing disease, and speed Lilly's return to profit growth.

Global company revenue fell 4 percent to $5.6 billion, little affected by foreign exchange rates, above Wall Street expectations of $5.36 billion.

Sales of Zyprexa, which lost U.S. patent protection in October, tumbled 56 percent to $563 million, while Cymbalta sales jumped 23 percent to $1.11 billion.

Although Cymbalta's growth helped offset declines for Zyprexa in the quarter, the depression drug's own U.S. patent will lapse in mid-2013. Its sales will then shrink dramatically, worsening Lilly's long-feared patent cliff.

Global sales of Alimta, the company's lung cancer drug, rose 5 percent to $607 million. Its Humalog insulin rose 12 percent to $590 million, while its Humulin insulin brand grew 6 percent to $308 million.

The company slightly raised its 2012 profit forecast to between $3.15 and $3.30 per share, excluding special items. In January, Lilly forecast $3.10 to $3.20 per share, far below analyst estimates, sending the drugmaker's stock down sharply.

(Reporting By Ransdell Pierson; Editing by Gerald E. McCormick and Maureen Bavdek)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELI LILLY AND COMPANY
07/20 ELI LILLY AND : Trademark Application for "BEFINVRA" Filed by Eli Lilly
07/20 ELI LILLY AND : Trademark Application for "RELVIZLYN" Filed by Eli Lilly
07/20 ELI LILLY AND : Renowned Television Personality Don Francisco Introduces New Ini..
07/20 ELI LILLY AND : Findings from Eli Lilly and Company Broaden Understanding of Dia..
07/20 ELI LILLY AND : New Findings in Type 2 Diabetes Described from Eli Lilly and Com..
07/20 ELI LILLY AND : Investigators at Eli Lilly and Company Describe Findings in DNA ..
07/20 ELI LILLY AND : FDA Grants Priority Review for Lilly's Abemaciclib for the Treat..
07/20 ELI LILLY AND : Trademark Application for "PLATFORM" Filed by Eli Lilly
07/20 ELI LILLY AND : Trademark Application for "INVESLYN" Filed
07/20 ELI LILLY AND : An Application for the Trademark "BEFYNVRA" Has Been Filed by El..
More news
News from SeekingAlpha
07/21 Ignyta Lights The Fire
07/21 United Therapeutics Losing The Crown Jewels; 20% EPS Downgrades Ahead
07/19 FDA's Flashing Green Light Boosts Novel Drug Approvals
07/19 Immunogen Finally Moving 'FORWARD'?
07/19 Gedeon Richter's antipsychotic med cariprazine approved in Europe
Financials ($)
Sales 2017 22 138 M
EBIT 2017 5 526 M
Net income 2017 3 251 M
Debt 2017 4 911 M
Yield 2017 2,47%
P/E ratio 2017 31,87
P/E ratio 2018 20,97
EV / Sales 2017 4,44x
EV / Sales 2018 4,33x
Capitalization 93 410 M
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | 4-Traders
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 90,2 $
Spread / Average Target 6,6%
EPS Revisions
Managers
NameTitle
David A. Ricks Chairman, President & Chief Executive Officer
Derica W. Rice Chief Financial Officer & EVP-Global Services
Jan M. Lundberg Executive Vice President-Science & Technology
Kathi P. Seifert Independent Director
Franklyn G. Prendergast Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
ELI LILLY AND COMPANY15.11%93 410
JOHNSON & JOHNSON17.45%364 503
ROCHE HOLDING LTD.4.90%221 492
NOVARTIS8.37%220 936
PFIZER3.08%199 378
MERCK AND COMPANY6.39%171 303